QNCXQuince Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Quince Therapeutics, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QNCXThis | $28M#8 | 0.2x#2 | — | — | — | -47.8%#11 | — | — | — | — | -91.4%#15 | — |
| TVGN | $50M#1 | — | — | — | — | -91.4%#13 | — | — | — | — | -81.8%#13 | — |
| TIL | $49M#3 | — | 0.5x#2 | — | -100.0%#7 | 3.7%#5 | — | -66.5%#3 | — | — | -68.4%#10 | — |
| BKHA | $49M#4 | — | — | — | — | -30.6%#10 | — | — | — | — | 126.3%#1 | 104.1%#1 |
| SCLX | $45M#5 | — | — | 1.5x#1 | -46.5%#5 | -413.8%#15 | -1143.7%#3 | — | — | 4#1 | -71.9%#11 | — |
| MGX | $43M#6 | — | 0.4x#1 | 1.7x#2 | -51.8%#6 | -12.6%#7 | -380.9%#2 | -78.1%#5 | — | — | -37.3%#5 | — |
| ATYR | $37M#7 | — | 0.8x#4 | 197.3x#5 | -19.1%#3 | -15.8%#8 | -40856.3%#6 | -151.9%#6 | -202.0%#2 | — | -64.3%#9 | — |
| ALGS | — | — | — | — | -39.5%#4 | 81.6%#2 | -4024.9%#4 | -75.9%#4 | — | — | -43.4%#7 | — |
| ESLA | $28M#10 | — | — | — | — | — | — | — | — | — | -41.4%#6 | — |
| CVM | $26M#11 | — | 2.4x#5 | 99.9x#4 | 65.5%#1 | 5.6%#4 | -9396.5%#5 | -231.9%#7 | — | — | -84.2%#14 | — |
| GRMLW | $28M#9 | — | 0.5x#3 | — | — | -71.6%#12 | — | -18.2%#2 | -14.6%#1 | — | -33.1%#3 | — |
| JSPR | $19M#12 | — | 13.7x#9 | — | — | 100.0%#1 | — | -0.0%#1 | — | — | -76.1%#12 | — |
| PHGE | $49M#2 | 0.1x#1 | 4.5x#7 | — | — | -104.2%#14 | — | -333.2%#9 | -377.8%#3 | — | -97.9%#16 | — |
| BCDA | $19M#13 | — | 6.9x#8 | — | -100.0%#7 | -3.5%#6 | — | -304.7%#8 | — | — | -27.9%#2 | — |
| PASG | $16M#14 | — | 3.5x#6 | — | — | 29.7%#3 | — | -1021.6%#10 | — | — | -34.2%#4 | — |
| DYAI | $15M#15 | — | — | 4.8x#3 | -11.6%#2 | -26.8%#9 | -232.8%#1 | — | — | — | -59.2%#8 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice